Foresee Pharmaceuticals Announces First Subject Dosed in First-in-Human Clinical Trial of FP-020



Taipei, April 30, 2024 /PRNewswire/—— Foresight Pharmaceutical Company (TPEx: 6576) (“Foresee”) today announced that the first subject has been dosed in the Phase 1 clinical trial of FP-020 Australia.

The Phase 1 clinical trial is a randomized, double-blind, placebo-controlled, single-center, single and multiple oral dose-escalation study designed to evaluate the safety, tolerability and drug substitution of FP-020 in healthy volunteers. dynamics. A maximum of 74 subjects will be enrolled at: Australia.

“We are pleased to announce the dosing of the first subject in this Phase 1 clinical study, marking an important milestone in the development of FP-020,” said Dr. FP-020. This dog, Chairman and CEO of Foresee. “The initiation of this Phase 1 trial underscores our commitment to advancing innovative therapies to benefit patients with severe asthma and COPD. Additionally, we are working to establish a pipeline of MMP-12 inhibitors across multiple therapeutic areas using our portfolio of A wide range of franchises.

“We are enthusiastic about the prospect of FP-020 as a best-in-class MMP-12 inhibitor, a pipeline drug opportunity with the potential for once-daily oral dosing,” said Dr. FP-020. Yang Wenjinchief scientific officer at Foresee.

About FP-020 and MMP-12

FP-020 is a highly potent, selective, oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases. FP-020 is a new generation MMP-12 inhibitor developed by Foresee after adrarestat. It exhibits superior pharmaceutical properties compared to adrarestat, with greater potency and similarly high selectivity. FP-020 has shown promising efficacy in multiple animal models of idiopathic pulmonary fibrosis and sarcoidosis. MMP-12 plays a role in asthma pathophysiology and correlates with disease severity. The Phase 2 proof-of-concept study of ademasstat in allergen-challenged asthma has been successfully completed.

A critical role for MMP-12 in disease is supported by single nucleotide polymorphism/genetic evidence associated with inflammatory fibrotic diseases, including asthma and chronic obstructive pulmonary disease. MMP-12 is a key immunofibrotic modulator secreted by macrophages and a key modulator of macrophage, neutrophil, and lung epithelial cell biology, and is increasingly recognized as a contributor to exacerbation of inflammation and fibrosis key mark.

about Forex Pharmaceutical Co., Ltd.

foresight is a Taiwan and a U.S. biopharmaceutical company listed on the Taipei Stock Exchange (TPEx: 6576). Foresee's R&D efforts are focused on two key areas, its unique stable injectable formulation (SIF) long-acting injectable technology and derivative drug products for specialty markets, and its transformative preclinical and clinical pipeline for rare and serious diseases. Best-in-class NCE programs disease areas with unmet need.

Foresee’s product portfolio includes late-stage and early-stage projects. CAMCEVI ® 42 mg for the treatment of advanced prostate cancer, now approved in the U.S. us, CanadaEU and Taiwan and launched in us exist April 2022. also, us EU regulatory documents are being prepared for CAMCEVI ® 21 mg. Second indication for CAMCEVI ® Phase 3 clinical study of 42 mg “central precocious puberty (CPP) Casppian has begun. FP-025” a highly selective oral MMP-12 inhibitor for inflammatory and fibrotic diseases, Phase 2 concept for patients with allergic asthma Validation studies have been completed with positive results and will be developed in the future in rare immunofibrotic diseases. FP-020 is a follow-up oral MMP-12 inhibitor currently in Phase 1, targeting severe asthma and chronic asthma. Obstructive Pulmonary Disease. FP-045, a highly selective, oral, small molecule allosteric activator of ALDH2, a mitochondrial enzyme, is currently initiating a Phase 1b/2 study in Fanconi anemia and pulmonary hypertension-interstitial disease. Lung disease (PH-ILD) patients are planned www.foreseepharma.com.

3rd party advertising. Not an offer or recommendation by Investing.com.See disclosures here or
Remove ads
.





Source link

Leave a Reply

Your email address will not be published. Required fields are marked *